Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Technologies (Paris:ERF) announces the launch of two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV. Since initial symptoms produced by these pathogens are indistinguishable, access to accurate and reliable tests will help clinicians improve patient care.
These new CE-marked multiplex kits have been specifically designed to detect and differentiate three viral infections in the same PCR run. The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay facilitates differentiation, in a single reaction, between Influenza A, B, and SARS-CoV-2, with simultaneous detection of two SARS-CoV-2 targets (N-gene + RdRP gene) as recommended by the WHO1. The RSV A, RSV B RT-PCR assay can differentiate between respiratory syncytial virus A and B.
Both kits can be processed in parallel on the same plate, using the same temperature profile, and provide results in approximately 1 hour. An internal control (RNaseP) is included for adequate sample processing, and to monitor RNA extraction and the presence of potential inhibitors in the RT-PCR reaction. The AriaDxTM and AriaMxTM thermocyclers from Agilent Technologies are validated for both assays. ABI Prism® 7500 Fast SDS and QuantStudioTM 5 from Applied Biosystems™, CFX96 Touch™ from Bio-Rad, and LightCycler® 480 II from Roche are validated for the RSV A, RSV B RT-PCR kit.
Co-circulation of respiratory tract viruses during the COVID-19 pandemic poses unprecedented challenges to healthcare systems worldwide, and Eurofins Technologies endeavours to continue to provide high quality solutions for multi-pathogen testing.
1 World Health Organization. (2020). Diagnostic testing for SARS-CoV-2: interim guidance, 11 September 2020. World Health Organization. https://apps.who.int/iris/handle/10665/334254.
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a decentralised and entrepreneurial network of 900 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 30 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.
Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
For further information: